Arcus Biosciences Inc Shares Close the Week 20.6% Higher - Weekly Wrap
The company saw its shares close the week 20.6% higher than last week, with trading volume higher than its 30 day average.
Jun 24, 2022 by Kwhen Finance Editors
Arcus Biosciences Inc (RCUS) shares closed this week 20.6% higher than it did at the end of last week. The stock is currently down 38.3% year-to-date, up 6.8% over the past 12 months, and up 46.9% over the past five years. This week, the Dow Jones Industrial Average rose 2.5%, and the S&P 500 rose 3.6%.
Trading Activity
- Shares traded as high as $24.98 and as low as $20.31 this week.
- Shares closed 48.0% below its 52-week high and 52.6% above its 52-week low.
- Trading volume this week was 18.0% lower than the 10-day average and 7.6% lower than the 30-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 1.7.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
- MACD, a trend-following momentum indicator, indicates an upward trend.
- The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance
- The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis
- The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis
- The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| Arcus Biosciences Inc | 2.3 | -38.3 | 6.8 | -49.1 | 49.3 |
| Dow Jones Industrial Average | 0.7 | -14.8 | -7.8 | -15.5 | 4.3 |
| S&P 500 Index | 1.0 | -19.8 | -9.3 | -19.9 | 5.3 |
| Health Care | 1.6 | -10.6 | -0.0 | -10.6 | 8.9 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date lags the peer average by 30.7%
- The company's stock price performance over the past 12 months beats the peer average by -120.4%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| Arcus Biosciences Inc | RCUS | 0 | -38.3 | 6.8 | -49.1 | 49.3 |
| Peer Avg | N/A | 0 | -29.3 | -33.1 | ||
| Ovid Therapeutics Inc | OVID | 0 | -41.4 | -55.6 | ||
| Oyster Point Pharma Inc | OYST | 0 | -75.7 | -76.7 | ||
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: